MedTrace Logo

Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients

NCT05774405 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9169

Last updated 2023-03-27

No results posted yet for this study

Summary

The goal of this randomized placebo-controlled study is to investigate the short-term effects of transdermal estrogen therapy on postmenopausal women with COVID-19 disease.

The main question\[s\] it aims to answer are:

* the clinical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease
* the biochemical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease

All participants received favipiravir for a week according to the national guidelines published by the Health Ministry of Turkish Republic at that time.

As an intervention, transdermal estradiol patch (7.8 mg patch/week) was applied for 14 days on the upper buttock of the patients in experimental arm. As a placebo, hydrogel patch (adhesive hydrogel patch/week) was applied to the female patients for 14 days.

Researchers compared experimental and control groups to see if the impact of adding estrogen on the clinical course of Covid-19 disease

Conditions

Interventions

DRUG

Climara 0.1Mg/24Hr Transdermal System

Transdermal estradiol patch is used.

OTHER

Hydrogel patch

Adhesive Hydrogel patch

Sponsors & Collaborators

  • Turkish Menopause and Osteoporosis Society

    collaborator UNKNOWN

  • Karakoy Rotary Club

    collaborator UNKNOWN

  • Rebul Pharmacy

    collaborator UNKNOWN

  • Istanbul University - Cerrahpasa

    lead OTHER

Principal Investigators

  • Cemal Tamer Erel, Prof · Istanbul University - Cerrahpasa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05774405 on ClinicalTrials.gov